Iguratimod can inhibit the expression of TNF-α, IL-1, IL-6 and MMP-9 to reduce bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice, suggesting that iguratimod may become an effective strategy for the treatment of pulmonary fibrosis (73). Here, IL1B is linked to pulmonary fibrosis.